Values as of: 2024-09-29
COMMON STOCK | Medical Devices |
Last Closing
USD 45.55Change
0.00 (0.00)%Market Cap
USD 3.06BVolume
0.53MAnalyst Target
USD 264.75Verdict
Verdict
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Company Website : https://www.quidelortho.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DXCM | DexCom Inc |
N/A |
USD 26.96B |
| PODD | Insulet Corporation |
N/A |
USD 16.27B |
| BRKR | Bruker Corporation |
N/A |
USD 10.70B |
| MASI | Masimo Corporation |
N/A |
USD 7.12B |
| TMDX | TransMedics Group Inc |
N/A |
USD 5.50B |
| PRCT | Procept Biorobotics Corp |
N/A |
USD 4.13B |
| AXNX | Axonics Modulation Technologie.. |
N/A |
USD 3.55B |
| TNDM | Tandem Diabetes Care Inc |
N/A |
USD 2.89B |
| LIVN | LivaNova PLC |
N/A |
USD 2.85B |
| UFPT | UFP Technologies Inc |
N/A |
USD 2.49B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -38.20% | 27% | F | 20% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -38.20% | 27% | F | 20% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -37.64% | 24% | F | 21% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -37.64% | 24% | F | 21% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -22.28% | 51% | F | 36% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -22.28% | 51% | F | 36% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -1.12% | N/A | N/A | 40% | F | ||
| Dividend Return | -1.12% | N/A | N/A | 36% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 82.49% | N/A | N/A | 21% | F | ||
| Risk Adjusted Return | -1.36% | N/A | N/A | 38% | F | ||
| Market Capitalization | 3.06B | 94% | A | 84% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
